A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Location: CPMC (San Francisco)
Please contact Clinicalresearch@sutterhealth.org about Study BrainstormNCT03280056
View study details on ClinicalTrials.gov
June 01, 2018
Investigator(s): Jonathan Katz, M.D.